Astellas To Take U.S. FDA To Court For Allowing Generic Of Prograf
This article was originally published in PharmAsia News
Executive SummaryAstellas Pharma says it plans to file a citizen petition against U.S. FDA over its decision to allow the marketing of a generic of the Astellas drug Prograf (tacrolimus) for preventing organ-transplant rejections. The issue centers on patent protection for the drug, which Astellas lost more than a year ago, and FDA's refusal to require generics to conduct their own clinical trials to compare the absorption of their versions with Prograf. Astellas said it also intends to demand labels on the generics to advise that physicians be notified when a pharmacist substitutes a generic for the branded drug. (Click here for more
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.